Pharmaceuticals Pfizer and Valneva hope to have developed a vaccine against Lyme disease by 2025. An ongoing study into this VLA15 will soon enter a new, very important phase, with fifty partners and 6000 test subjects from five years old worldwide.
–
Amsterdam UMC will participate in this. With how many test subjects can be announced only after all procedures have also been formally approved there. In addition to the Netherlands, the study will be conducted in Finland, Germany, Poland, Sweden and the United States, countries where Lyme is common.
One and a half million
Ticks appear more and more often, while a bite is often not noticed quickly enough. According to the RIVM, about one and a half million get a tick bite in our country every year. About 27,000 get Lyme disease, of whom 1000 to 1500 people have long-term complaints.
Pfizer CEO Annaliesa Anderson calls a new Lyme drug “more important than ever”. Valneva CEO Juan Carlos Jaramillo speaks of an “important milestone”. (ANP)
<!–
–>
–
